Tribe Clinical Research Leads Final-Stage Remternetug Study After 40 Upstate Patients Take Alzheimer’s Drug
Updated
Updated · WYFF4 Greenville · Jul 31
Tribe Clinical Research Leads Final-Stage Remternetug Study After 40 Upstate Patients Take Alzheimer’s Drug
1 articles · Updated · WYFF4 Greenville · Jul 31
Summary
Tribe Clinical Research in Greenville is leading late-stage research on remternetug, an Alzheimer’s drug CEO Jennifer Lehman said is nearing FDA approval.
Remternetug targets an abnormal protein linked to Alzheimer’s, with the study aimed at showing it can slow disease progression and help patients remain independent longer.
At least 40 Upstate patients have already taken the drug in the trial, capping about 18 months of work by the clinic on the program.
The remternetug registry is no longer enrolling, though the clinic said it is still seeking volunteers for several other research studies.
As remternetug moves closer to possible approval, how does this next-generation Alzheimer’s therapy compare with existing anti-amyloid drugs on safety and convenience?
Could a Greenville trial help prove whether remternetug slows Alzheimer’s before independence is lost—and what risks come with targeting amyloid this early?